Minimal change glomerulopathy in a cat

J Feline Med Surg. 2011 Apr;13(4):291-5. doi: 10.1016/j.jfms.2010.12.011.

Abstract

A 6-year-old domestic shorthair male castrated cat was evaluated for sudden onset of vomiting and anorexia. A diagnosis of hypereosinophilic syndrome (HES) was made, and the cat was treated with imatinib mesylate. The cat had an initial clinical improvement with the normalization of the peripheral eosinophil count. After approximately 8 weeks of treatment, lethargy and anorexia recurred despite the normal eosinophil count and a significant proteinuric nephropathy was identified. Treatment with imatinib was discontinued. Ultrasound guided renal biopsies exhibited histologic, ultrastructural, and immunostaining changes indicative of a minimal change glomerulopathy (MCG) which has not previously been reported in the literature in a cat. The proteinuria and HES initially improved while the cat was treated with more traditional medications; however, both the problems persisted for 30 months that the cat was followed subsequently. Previous studies demonstrating the safety and efficacy of imatinib in cats do not report any glomerular injury or significant adverse drug reactions, and the exact cause of this cat's proteinuric nephropathy is uncertain. Nonetheless, the possibility of an adverse drug reaction causing proteinuria should be considered when initiating treatment with imatinib in a cat.

Publication types

  • Case Reports

MeSH terms

  • Animals
  • Benzamides
  • Cat Diseases / diagnosis*
  • Cat Diseases / drug therapy
  • Cats
  • Hypereosinophilic Syndrome / diagnosis
  • Hypereosinophilic Syndrome / drug therapy
  • Hypereosinophilic Syndrome / veterinary*
  • Imatinib Mesylate
  • Leukocyte Count / veterinary
  • Male
  • Nephrosis, Lipoid / diagnosis
  • Nephrosis, Lipoid / drug therapy
  • Nephrosis, Lipoid / etiology
  • Nephrosis, Lipoid / veterinary*
  • Piperazines / adverse effects*
  • Piperazines / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases